MAIA (MAIA) Chief Scientific Officer purchases 2,000 company shares in market trade

Rhea-AI Filing Summary

MAIA Biotechnology, Inc. Chief Scientific Officer Sergei Gryaznov reported an open-market purchase of 2,000 shares of Common Stock on June 1, 2026 at a price of $1.345 per share. Following this transaction, he directly holds 46,511 shares of MAIA Biotechnology Common Stock.

Insider Trade Summary

Net Buyer: 2,000 shares ($2,690)

Net Buy 1 txn

Insider Gryaznov Sergei

Role Chief Scientific Officer

Bought 2,000 shs ($3K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	2,000	$1.345	$3K

Holdings After Transaction: Common Stock — 46,511 shares (Direct, null)

Footnotes (1)

Key Figures

Shares purchased: 2,000 shares Purchase price: $1.345 per share Post-transaction holdings: 46,511 shares +1 more

4 metrics

Shares purchased 2,000 shares Open-market purchase on June 1, 2026

Purchase price $1.345 per share Price paid for MAIA Common Stock

Post-transaction holdings 46,511 shares Direct ownership after the transaction

Net buy shares 2,000 shares Net buy-sell direction reported as net-buy

Key Terms

open-market purchase, Common Stock, Form 4, direct ownership

4 terms

open-market purchase financial

"transaction_action is described as an open-market purchase of Common Stock"

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

Common Stock financial

"The security title for the transaction is listed as Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 regulatory

"Insider transaction is disclosed on SEC Form 4 for MAIA"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

direct ownership financial

"Ownership type is reported as direct with code D"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gryaznov Sergei

(Last) (First) (Middle)

444 WEST LAKE STREET,

(Street)

CHICAGO ILLINOIS 60606

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MAIA Biotechnology, Inc. [ MAIA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/01/2026		P		2,000	A	$1.345	46,511	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Sergei M. Gryaznov	06/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did MAIA (MAIA) report for Sergei Gryaznov?

MAIA reported that Chief Scientific Officer Sergei Gryaznov purchased 2,000 shares of Common Stock. The open-market transaction occurred on June 1, 2026, and was reported on Form 4 as a direct ownership position in the company’s stock.

At what price did Sergei Gryaznov buy MAIA (MAIA) shares?

Sergei Gryaznov bought 2,000 MAIA Biotechnology Common Stock shares at $1.345 per share. This price reflects the per-share cost disclosed for the open-market purchase reported in the Form 4 insider transaction filing.

How many MAIA (MAIA) shares does Sergei Gryaznov hold after this transaction?

After the reported transaction, Sergei Gryaznov directly holds 46,511 shares of MAIA Biotechnology Common Stock. This post-transaction balance is disclosed in the Form 4 as his total direct ownership following the June 1, 2026 open-market purchase.

What type of insider transaction was reported for MAIA (MAIA) on June 1, 2026?

The transaction was an open-market purchase of Common Stock by Chief Scientific Officer Sergei Gryaznov. It is coded as a “P” transaction on Form 4, indicating a purchase in the open market or a private transaction under SEC rules.

Does Sergei Gryaznov’s MAIA (MAIA) transaction involve derivatives or options?

The reported Form 4 transaction for Sergei Gryaznov involves only non-derivative Common Stock. The derivative summary is empty, indicating no option exercises, warrant conversions, or other derivative transactions were disclosed in this particular insider filing.